Search Results - "Abdeen, Sanofar J"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
  2. 2
  3. 3

    FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein by Miller, Christina J., McGinnis, Jennifer E., Martinez, Michael J., Wang, Guangli, Zhou, Jian, Simmons, Erica, Amet, Tohti, Abdeen, Sanofar J., Van Huysse, James W., Bowsher, Ronald R., Kay, Brian K.

    Published in New biotechnology (25-05-2021)
    “…•Monobodies were generated via phage-display to the SARS-CoV-2 spike protein.•Affinities of the monobodies for the RBD are estimated between 3 and 14 nM.•The…”
    Get full text
    Journal Article
  4. 4

    Critical reagent inventory management system and web portal specifically optimized for supporting external clients by Feauto, Jessica A, Davis, Aleks, Delhaye, Richard C, Abdeen, Sanofar J, Gill, Hannah N, Colwell, Jamie E, Chiappetta, Michael, Clor, Emma E, Bowsher, Ronald R

    Published in Bioanalysis (01-06-2022)
    “…High-quality critical reagents are essential for the establishment of robust ligand binding assays to support regulated bioanalysis. To ensure consistency in…”
    Get full text
    Journal Article
  5. 5

    Peptide Inhibitors Targeting Clostridium difficile Toxins A and B by Abdeen, Sanofar J, Swett, Rebecca J, Feig, Andrew L

    Published in ACS chemical biology (17-12-2010)
    “…Clostridium difficile causes severe hospital-acquired antibiotic-associated diarrhea due to the activity of two large protein toxins. Current treatments suffer…”
    Get full text
    Journal Article
  6. 6

    Generation of Affinity Purified Antibody Reagents for Specific Determination of Efruxifermin in Biological Matrices by Kinne, Adam S, Abdeen, Sanofar J, Parmer, Elijah S, Thystrup, Jennifer A, Tillman, Erik J, Rolph, Timothy P, Bowsher, Ronald R

    Published in Journal of the Endocrine Society (03-05-2021)
    “…Efruxifermin (EFX) is a novel Fc-fusion analog of human fibroblast growth factor 21 (FGF21), currently in clinical development as a potential treatment for…”
    Get full text
    Journal Article
  7. 7

    Development of peptide inhibitors targeting Clostridium difficile toxins A/B and characterizing the regulatory role of a putative negative regulator TcdC in Clostridium difficile toxin gene expression by Abdeen, Sanofar J

    Published 01-01-2013
    “…Clostridium difficile infections cause one of the most common and vital hospitalacquired diseases often associated with broad-spectrum antibiotic usage. TcdA…”
    Get full text
    Dissertation
  8. 8

    Development of peptide inhibitors targeting Clostridium difficile toxins A/B and characterizing the regulatory role of a putative negative regulator TcdC in Clostridium difficile toxin gene expression by Abdeen, Sanofar J

    “…Clostridium difficile infections cause one of the most common and vital hospitalacquired diseases often associated with broad-spectrum antibiotic usage. TcdA…”
    Get full text
    Dissertation